Ost-müük Nautilus Biotechnology, Inc. - NAUT CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Kauplemistingimused
| Hinnavahe | - | ||||||||
|
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
|
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
| Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
| Min kauplemise kogus | 1 | ||||||||
| Valuuta | USD | ||||||||
| Tagatis | 20% | ||||||||
| Aktsiabörs | United States of America | ||||||||
| Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Võtmestatistika
| Eelmine sulgemine* | N/A |
| Avatud* | N/A |
| Aastane muutus* | N/A |
| Päeva ulatus* | N/A |
| 52 nädala ulatus | 1.50-5.07 |
| Keskmine maht (10 päeva) | 170.96K |
| Keskmine maht (3 kuud) | 2.84M |
| Turukapitalisatsioon | 282.20M |
| P/E suhtarv | -100.00K |
| Ringluses olevad aktsiad | 124.87M |
| Tulu | N/A |
| EPS | -0.46 |
| Dividendid (% kasumist) | N/A |
| Beeta | -100.00K |
| Järgmine tuluaruande kuupäev | N/A |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
|---|
Nautilus Biotechnology, Inc. Events
| Kellaaeg (UTC) (UTC) | Riik | Sündmus |
|---|---|---|
| No events scheduled | ||
- Aastas
- Kvartalis
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Kogutulu | 0 | 0 | 0 |
| Kogu tegevuskulu | 10.11 | 15.744 | 50.498 |
| Müük/Üldine/admin kulud, kokku | 1.622 | 3.312 | 21.146 |
| Uuringud ja arendus | 8.488 | 12.432 | 28.352 |
| Tulud majandustegevusest | -10.11 | -15.744 | -50.498 |
| Muud, neto | 0.492 | 0.125 | 0.183 |
| Netotulu enne makse | -9.618 | -15.619 | -50.315 |
| Netotulu pärast makse | -9.618 | -15.619 | -50.315 |
| Netotulu enne erikulusid | -9.618 | -15.619 | -50.315 |
| Netotulu | -9.618 | -15.619 | -50.315 |
| Arvestatav tulu, v a erikulud | -9.618 | -15.619 | -50.315 |
| Arvestatav tulu, koos erikuludega | -9.618 | -15.619 | -50.315 |
| Jaotamisele kuuluv netotulu | -9.618 | -15.619 | -50.315 |
| Keskmine jaotamisele kuuluv aktsia kohta | 124.094 | 124.094 | 124.303 |
| Jaotatav EPS, v a erakorralised kulud | -0.07751 | -0.12586 | -0.40478 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 |
| Jaotamisele kuuluv normaal-EPS | -0.07751 | -0.12586 | -0.40478 |
| Depreciation / Amortization | 1 |
| Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
|---|---|---|---|---|---|
| Kogutulu | 0 | 0 | 0 | 0 | 0 |
| Kogu tegevuskulu | 8.417 | 10.697 | 14.568 | 16.816 | 16.022 |
| Müük/Üldine/admin kulud, kokku | 3.582 | 4.317 | 6.324 | 6.923 | 6.364 |
| Uuringud ja arendus | 4.835 | 6.38 | 8.244 | 9.893 | 9.658 |
| Tulud majandustegevusest | -8.417 | -10.697 | -14.568 | -16.816 | -16.022 |
| Muud, neto | 0.008 | -0.016 | 0.064 | 0.127 | 0.259 |
| Netotulu enne makse | -8.409 | -10.713 | -14.504 | -16.689 | -15.763 |
| Netotulu pärast makse | -8.409 | -10.713 | -14.504 | -16.689 | -15.763 |
| Netotulu enne erikulusid | -8.409 | -10.713 | -14.504 | -16.689 | -15.763 |
| Netotulu | -8.409 | -10.713 | -14.504 | -16.689 | -15.763 |
| Arvestatav tulu, v a erikulud | -8.409 | -10.713 | -14.504 | -16.689 | -15.763 |
| Arvestatav tulu, koos erikuludega | -8.409 | -10.713 | -14.504 | -16.689 | -15.763 |
| Jaotamisele kuuluv netotulu | -8.409 | -10.713 | -14.504 | -16.689 | -15.763 |
| Keskmine jaotamisele kuuluv aktsia kohta | 124.094 | 124.094 | 124.094 | 124.303 | 124.419 |
| Jaotatav EPS, v a erakorralised kulud | -0.06776 | -0.08633 | -0.11688 | -0.13426 | -0.12669 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | 0 |
| Jaotamisele kuuluv normaal-EPS | -0.06776 | -0.08633 | -0.11688 | -0.13426 | -0.12669 |
- Aastas
- Kvartalis
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Käibevarad kokku | 16.964 | 77.659 | 349.222 |
| Raha ja lühiajalised investeeringud | 16.659 | 76.742 | 345.729 |
| Raha ja ekvivalendid | 0.595 | 36.607 | 185.619 |
| Lühiajalised investeeringud | 16.064 | 40.135 | 160.11 |
| Prepaid Expenses | 0.305 | 0.917 | 3.493 |
| Total Assets | 18.542 | 85.011 | 398.45 |
| Property/Plant/Equipment, Total - Net | 1.119 | 6.213 | 31.86 |
| Property/Plant/Equipment, Total - Gross | 1.868 | 7.498 | 33.854 |
| Accumulated Depreciation, Total | -0.749 | -1.285 | -1.994 |
| Other Long Term Assets, Total | 0.459 | 1.139 | 0.997 |
| Total Current Liabilities | 0.49 | 3.018 | 5.812 |
| Accounts Payable | 0.289 | 0.47 | 1.723 |
| Accrued Expenses | 0.201 | 2.548 | 4.089 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 |
| Total Liabilities | 0.49 | 6.314 | 34.874 |
| Total Long Term Debt | 0 | 0 | 0 |
| Other Liabilities, Total | 0 | 3.296 | 29.062 |
| Total Equity | 18.052 | 78.697 | 363.576 |
| Preferred Stock - Non Redeemable, Net | 32.561 | 108.418 | 0 |
| Common Stock | 0.001 | 0.001 | 0.012 |
| Additional Paid-In Capital | 0.189 | 0.6 | 444.388 |
| Retained Earnings (Accumulated Deficit) | -14.706 | -30.325 | -80.64 |
| Other Equity, Total | 0.007 | 0.003 | -0.184 |
| Total Liabilities & Shareholders’ Equity | 18.542 | 85.011 | 398.45 |
| Total Common Shares Outstanding | 124.094 | 124.094 | 124.303 |
| Long Term Investments | 16.371 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Käibevarad kokku | 69.445 | 374.628 | 352.222 | 349.222 | 327.065 |
| Raha ja lühiajalised investeeringud | 67.837 | 373.144 | 347.345 | 345.729 | 324.117 |
| Raha ja ekvivalendid | 51.803 | 288.387 | 190.241 | 185.619 | 188.622 |
| Lühiajalised investeeringud | 16.034 | 84.757 | 157.104 | 160.11 | 135.495 |
| Prepaid Expenses | 1.608 | 1.484 | 4.877 | 3.493 | 2.948 |
| Total Assets | 76.148 | 393.275 | 385.347 | 398.45 | 384.673 |
| Property/Plant/Equipment, Total - Net | 2.889 | 2.769 | 5.731 | 31.86 | 31.693 |
| Property/Plant/Equipment, Total - Gross | 4.388 | 4.533 | 7.772 | 33.854 | 33.968 |
| Accumulated Depreciation, Total | -1.499 | -1.764 | -2.041 | -1.994 | -2.275 |
| Other Long Term Assets, Total | 3.814 | 0.612 | 0.767 | 0.997 | 0.997 |
| Total Current Liabilities | 4.525 | 3.231 | 4.209 | 5.812 | 6.406 |
| Accounts Payable | 2.12 | 1.229 | 1.498 | 1.723 | 1.487 |
| Accrued Expenses | 2.405 | 2.002 | 2.711 | 4.089 | 4.919 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 4.525 | 3.231 | 7.5 | 34.874 | 34.964 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 0 | 0 | 3.291 | 29.062 | 28.558 |
| Total Equity | 71.623 | 390.044 | 377.847 | 363.576 | 349.709 |
| Preferred Stock - Non Redeemable, Net | 108.418 | 0 | 0 | ||
| Common Stock | 0.001 | 0.012 | 0.012 | 0.012 | 0.012 |
| Additional Paid-In Capital | 1.936 | 439.489 | 441.795 | 444.388 | 446.654 |
| Retained Earnings (Accumulated Deficit) | -38.734 | -49.447 | -63.951 | -80.64 | -96.403 |
| Other Equity, Total | 0.002 | -0.01 | -0.009 | -0.184 | -0.554 |
| Total Liabilities & Shareholders’ Equity | 76.148 | 393.275 | 385.347 | 398.45 | 384.673 |
| Total Common Shares Outstanding | 124.094 | 124.094 | 124.094 | 124.303 | 124.457 |
| Long Term Investments | 15.266 | 26.627 | 16.371 | 24.918 |
- Aastas
- Kvartalis
| 2019 | 2020 | 2021 | |
|---|---|---|---|
| Netotulu/algväärtus | -50.315 | ||
| Raha majandustegevusest | -39.241 | ||
| Raha majandustegevusest | 1.019 | ||
| Mittelikviidsed varad | 10.077 | ||
| Muutused tööjõus | -0.022 | ||
| Tulu investeeringutelt | -138.964 | ||
| Kapitalikulutused | -2.269 | ||
| Muud rahavood investeeringutelt, kokku | -136.695 | ||
| Rahavood investeeringutelt | 327.447 | ||
| Rahavoogudesse investeerimine | 327.28 | ||
| Aktsiate emiteerimine (tagasiost), neto | 0.167 | ||
| Rahaline kogumuutus | 149.242 |
| Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -8.409 | -19.122 | -33.626 | -50.315 | -15.763 |
| Cash From Operating Activities | -6.253 | -14.545 | -28.722 | -39.241 | -12.335 |
| Cash From Operating Activities | 0.214 | 0.479 | 0.756 | 1.019 | 0.281 |
| Non-Cash Items | 1.864 | 4.129 | 6.811 | 10.077 | 2.661 |
| Changes in Working Capital | 0.078 | -0.031 | -2.663 | -0.022 | 0.486 |
| Cash From Investing Activities | 23.518 | -61.048 | -145.028 | -138.964 | 15.182 |
| Other Investing Cash Flow Items, Total | 23.518 | -60.035 | -143.745 | -136.695 | 15.663 |
| Cash From Financing Activities | -2.069 | 327.373 | 327.384 | 327.447 | 0.156 |
| Financing Cash Flow Items | -2.069 | 327.327 | 327.28 | 327.28 | 0 |
| Net Change in Cash | 15.196 | 251.78 | 153.634 | 149.242 | 3.003 |
| Capital Expenditures | -1.013 | -1.283 | -2.269 | -0.481 | |
| Issuance (Retirement) of Stock, Net | 0.046 | 0.104 | 0.167 | 0.156 |
| Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
|---|---|---|---|---|---|---|
| Mallick (Parag) | Individual Investor | 16.5616 | 20679892 | 200000 | 2022-04-18 | LOW |
| Patel (Sujal M) | Individual Investor | 13.7018 | 17108999 | 0 | 2023-02-27 | LOW |
| Perceptive Advisors LLC | Private Equity | 7.2967 | 9111151 | 0 | 2022-12-31 | MED |
| Cercano Management LLC | Investment Advisor | 5.7445 | 7172985 | 7172985 | 2022-12-31 | |
| Vulcan Capital Management Inc | Corporation | 5.7445 | 7172985 | 0 | 2022-04-18 | |
| Madrona Venture Group, LLC | Venture Capital | 4.8218 | 6020770 | 0 | 2022-12-31 | LOW |
| ARYA Sciences Holdings III | Corporation | 3.3207 | 4146500 | 3647500 | 2022-04-18 | |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 2.1231 | 2651020 | 144356 | 2022-12-31 | LOW |
| Comprehensive Financial Management LLC | Investment Advisor | 1.7816 | 2224619 | 0 | 2022-12-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.7422 | 2175376 | -1313 | 2022-12-31 | LOW |
| Bain Capital Life Sciences Investors, LLC | Investment Advisor | 1.6017 | 2000000 | 0 | 2022-12-31 | LOW |
| Nazem (Farzad) | Individual Investor | 1.5121 | 1888146 | 0 | 2022-04-18 | LOW |
| Tikvah Management LLC | Hedge Fund | 1.1924 | 1488895 | 0 | 2022-12-31 | LOW |
| Amazon.com Inc | Investment Advisor | 1.1669 | 1457055 | 0 | 2022-12-31 | LOW |
| ArchPoint Investors, LLC | Investment Advisor | 1.1609 | 1449551 | 0 | 2022-12-31 | LOW |
| Andreessen Horowitz | Venture Capital | 1.0859 | 1355911 | -16298006 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7695 | 960868 | 5799 | 2022-12-31 | LOW |
| Rubric Capital Management LP | Hedge Fund | 0.5987 | 747607 | 0 | 2022-12-31 | MED |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.5624 | 702204 | 49879 | 2022-12-31 | LOW |
| RTW Investments L.P. | Investment Advisor/Hedge Fund | 0.4805 | 600000 | 0 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group 500000+
Kauplejad
92000+
Igakuiste aktiivsete klientide arv
$53000000+
Igakuine investeerimise maht
$30000000+
Proovige nüüd Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
Kauplemise vahendustasu
0
- 1:1
Finantsvõimendus
1:1
- 20
- 100
- 500
- 1000
- 10000
Investeering
Tehingu suurus (võimendus x investeering):
Avamishind
Close
Lühike Pikk
Nautilus Biotechnology, Inc. Company profile
Ettevõttest Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. on arendusjärgus bioteaduste ettevõte. Ettevõte tegeleb platvormtehnoloogia loomisega inimese proteoomi keerukuse kvantifitseerimiseks ja avamiseks. Ettevõte keskendub proteoomika valdkonna muutmisele, demokratiseerides juurdepääsu proteoomile ja võimaldades fundamentaalset arengut kogu inimtervishoiu ja -meditsiini valdkonnas. Ettevõtte platvormi terviklahendus koosneb proteoomi analüüsisüsteemist, tarbekaupadest ja tarkvarast. Ettevõte töötab välja prototüüpi ühe molekuli instrumenti, proteoomianalüüsi süsteemi. Ettevõtte proteoomianalüüsi platvorm kasutab nanotehnoloogilist ühemolekulaarset valkude massiivi, mitmekordset pildistamist ja masinõppe analüüsi, et tuvastada ja mõõta proteoomi tundlikult ja mastaapselt.
| Industry: | Biotechnology & Medical Research (NEC) |
2701 Eastlake Ave East
Suite 202
SEATTLE
WASHINGTON 98102
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com